26
Participants
Start Date
July 17, 2019
Primary Completion Date
June 3, 2022
Study Completion Date
March 20, 2024
Sacituzumab Govitecan
All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
Mays Cancer Center, UT Health San Antonio, San Antonio
Collaborators (1)
Gilead Sciences
INDUSTRY
The University of Texas Health Science Center at San Antonio
OTHER